Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM6J5Z)

Drug Name
PQ-912 Drug Info
Indication
Disease Entry ICD 11 Status REF
Dementia 6D80-6D86 Phase 2 [1]
Cross-matching ID
PubChem CID
51030870
CAS Number
CAS 1276021-65-8
TTD Drug ID
DMM6J5Z

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glutaminyl cyclase (QPCT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PBD150 DM1Y2F0 Discovery agent N.A. Investigative [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutaminyl cyclase (QPCT) TTJ7YTV QPCT_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02389413) Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease. U.S. National Institutes of Health.
2 Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer s Disease ImmunotherapyRoxanna Perez-Garmendia, Goar Gevorkian. Curr Neuropharmacol. 2013 September; 11(5): 491-498.
3 The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. J Med Chem. 2006 Jan 26;49(2):664-77.